CLINICAL TRIALS

Joseph A. Lasky, M.D.

A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (L0320)

An Open-Label Extension Study of the Long Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies

CQAX576A2202: An open label, multi-center study, with a single intravenous dose of QAX576 to determine IL-13 production in patients with Idiopathic Pulmonary Fibrosis

Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis

PANTHER:  Prednisone, Azathioprine, N-Acetylcysteine A Study That Evaluates Response to Idiopathic Pulmonary Fibrosis

ACE: AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

For further information contact: Sandy Ditta @ (504) 988-4040 or email: sditta@tulane.edu

Francesco Simeone, M.D.

Prospective, Randomized, Multi-center Trial of Initial Trophic Enteral Feeding Followed by Advancement to Full-Calorie Enteral Feeding vs. Early Advancement to Full-Calorie Enteral Feeding in Patients with Acute Lung Injury (ALI) or Acute Respiratory Distress

Syndrome (ARDS) and Prospective, Randomized, Blinded, Placebo-controlled, Multi-center Trial of Omega-3 Fatty Acid, Gamma-Linolenic Acid, and Anti-Oxidant Supplementation in the Management of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)